Adlai Nortye, a Hangzhou biopharma that describes itself as “science-driven,” opened a Boston site that will serve as the target validation and translational medicine center of the company. The center will be in charge of developing new cancer treatments, especially clinical-stage immuno-oncology candidates. Adlai Nortye expects its Boston operations will help it form more partnerships with global biopharmas. The company is developing cancer immunotherapies and treatments for metabolic disease.
Source: China Biotoday
